All News

#0513 🔬 Rituximab in RA: IgG levels & infection ➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs) 🧬 IgG levels ⬇️over time (6 years/25 infusions) ⚠️ Infection-related hospitalizations peaked year 1 ⬆️risk w/ concurrent steroid(HR 2.1,p=0.002) #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7

Links:

Jiha Lee JihaRheum ( View Tweet)
Discrimination in #SLE is a chronic stressor - Asians had substantial levels along with association of worse mental health and SLE activity Data from the California Lupus Epidemiology Study (CLUES) using the Everyday Discrimination Scale (EDS) @JYazdany @RheumNow #ACR24 abst#0171

Bella Mehta bella_mehta ( View Tweet)

Clauw: think of THC and CBD as “completely different” Cannabidiol - safe, not psychoactive, “can use liberally” THC - psychoactive with effects on CB1 and CB2 receptors. CB1 affects the brain where CB2 is more in inflammation #ACR24 @RheumNow https://t.co/A0TgSpAO64

Links:

Eric Dein ericdeinmd ( View Tweet)
Cardiology 🤝 Rheumatology #Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort @RheumNow #ACR24 https://t.co/jLLYNOfFZ2

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
Moderating a great talk about POTS - great slide & nice presentation technique Dr. Adler flashed a screen of the ROS for pts w/POTs, overwhelming as expected… then overlaid common causes and phenotypes - really like this as a framework! #ACR24 @RheumNow https://t.co/mCmtygxxv4

Links:

Mike Putman EBRheum ( View Tweet)
🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis. Another innovation that may help with the rapid… https://t.co/qSwryK22uj

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

#0456📱 Digital Health & RA ePROs 💻Rx response in 150 RA patients using ePROs & actigraphy 🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone) 💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden. #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk. @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi

Links:

Richard Conway RichardPAConway ( View Tweet)
Happening now: 16S18 Into the Weeds: Cannabis in Rheum @EleniTiniakou @BharatKumarMD Do you discuss marijuana with your patients? @RheumNow #ACR24

Eric Dein ericdeinmd ( View Tweet)

Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https://t.co/OhqTJZQwKX https://t.co/RTQUjE6lLy

Links:

Richard Conway RichardPAConway ( View Tweet)
Abstr#0647 Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores - Tx: GC, HCQ, AZA @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

Abstract #0614 What is the impact of Lupus on my quality of life? Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM) - high dose GC, comorbidities, and not actively working associated with worse impact on QoL - HCQ shows benefit @RheumNow #ACR24

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

#0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

×